Recent News

• 05.27.2025 - Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
• 05.15.2025 - Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
• 05.05.2025 - Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
• 04.29.2025 - Immutep Quarterly Activities Report Q3 FY25
• 04.02.2025 - Immutep to Participate in Upcoming Investor Conferences
• 03.25.2025 - First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
• 03.20.2025 - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
• 01.31.2025 - Immutep Quarterly Activities Report Q2 FY25

Recent Filings

• 05.16.2025 - EX-99.1 EX-99.1
• 05.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.06.2025 - EX-99.1 EX-99.1
• 04.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - EX-99.1 EX-99.1
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.27.2025 - EX-99.1 EX-99.1